GlassScriptPhysician profile
Karl Doghramji
NPI 1336229459
$84,594.00
in general payments reported to CMS, 2019-2025
16 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $16K · 2021: $22K · 2022: $18K · 2023: $13K · 2024: $4,540 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,909 · Consulting Fee: $7,789 · Honoraria: $1,000 · Travel and Lodging: $805 · Food and Beverage: $474 · Education: $33.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,908.75 |
| Consulting Fee | $7,789.00 |
| Honoraria | $1,000.00 |
| Travel and Lodging | $804.73 |
| Food and Beverage | $473.80 |
| Education | $33.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21,620.29 | 2020-2025 | |
| Eisai INC. | $17,923.52 | 2019-2022 | |
| Harmony Biosciences LLC | $16,123.77 | 2020-2024 | Wakix |
| Idorsia Pharmaceuticals US INC | $13,737.45 | 2022-2023 | Quviviq |
| Imbrium Therapeutics L.P. | $4,500.00 | 2021 | |
| Biogen, INC. | $3,101.00 | 2023 | |
| Natus Medical Incorporated | $3,000.00 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $2,903.75 | 2022 | |
| Pfizer INC. | $700.00 | 2019 | |
| Inspire Medical Systems, INC. | $650.00 | 2021 | |
| Zoll Respicardia, INC. | $140.79 | 2021 | |
| Allergan, INC. | $104.90 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $41.61 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $16.69 | 2023 | Sunosi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2025 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $13.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Doghramji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.